CNS PHARMACEUTICALS AG

99 articles with CNS PHARMACEUTICALS AG

• CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/15/2022

  CNS PHARMACEUTICALS AG Inc. today reported its financial results for the quarter ended June 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

• CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

  7/25/2022

  Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at their discretion.

• CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

  6/23/2022

  Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM.

• CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

  6/8/2022

  CNS Pharmaceuticals, Inc. today announced that Sigmund Hsu , MD, member of the Company's Scientific Advisory Board, presented an overview of its ongoing clinical trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

• CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

  5/24/2022

  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will be participating at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

• CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

  5/18/2022

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

• CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update.

• CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

  4/28/2022

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced it has received approval from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

• CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

  4/12/2022

  CNS Pharmaceuticals, Inc. announced it will participate in the Virtual Investor Glioblastoma Multiforme Spotlight event on Thursday, April 14th at 11:30 AM ET.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

  4/6/2022

  CNS Pharmaceuticals, Inc. today announced it has received approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and from the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

• CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

  4/5/2022

  CNS Pharmaceuticals, Inc. today announced it has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the Company's potentially pivotal study of Berubicin.

• CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

  3/23/2022

  CNS Pharmaceuticals, Inc. announced that John Climaco, CEO of CNS Pharmaceuticals will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.

• CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders

  3/9/2022

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity.

• CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

  3/3/2022

  CNS Pharmaceuticals, Inc. today reported its financial results for the year ended December 31, 2021 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

• CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

  1/20/2022

  CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 11:00 AM ET.

• CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  1/10/2022

  CNS Pharmaceuticals, Inc. announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 12,105,264 shares of common stock.

• CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

  1/7/2022

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

• CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

  12/2/2021

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced it has received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, for the Company's potentially pivotal study of Berubicin.

• CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

  11/16/2021

  Live moderated video webcast discussion among members of management on Thursday, November 18th at 9:00 AM ET